• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Admedus Ltd.

Admedus deals biologic patch business to LeMaitre Vascular for $24m

October 15, 2019 By Brad Perriello

Admedus (ASX:AHZ) dealt its biologic patch business to LeMaitre Vascular (NSDQ:LMAT) in a deal worth up to $24.6 million to focus on the transcatheter aortic valve replacement market. The A$36.2 million buyout of the CardioCel and VascuCel patches called for LeMaitre to put up $14.2 million up front, with another $1.4 million due in a pair […]

Filed Under: Featured, Mergers & Acquisitions, Regenerative Medicine, Vascular, Wall Street Beat, Wound Care Tagged With: Admedus Ltd., LeMaitre Vascular Inc.

Admedus deals vaccines biz to Constellation Therapeutics

April 10, 2019 By Brad Perriello

Admedus (ASX:AHZ) said today that it agreed to sell its vaccines business to Constellation Therapeutics in a deal that will see it own nearly 30% of the Chinese company. Other shareholders in the vaccines would own another 11%, Queensland, Australia-based Admedus said. Sun Bright Holdings will own the remainder and put in $18 million until November […]

Filed Under: Featured, Mergers & Acquisitions, Regenerative Medicine, Wall Street Beat Tagged With: Admedus Ltd.

Admedus wins CE Mark for CardioCel 3D, VascuCel products

March 12, 2019 By Fink Densford

Admedus (ASX:AHZ)  has won CE Mark approval in the European Union for its CardioCel 3D and VascuCel products which use its proprietary Adapt tissue technology, according to a report from ProactiveInvestors. The Australian company plans to begin the first stage of a commercial launch of the devices in the region later this month, according to the […]

Filed Under: Regenerative Medicine, Regulatory/Compliance Tagged With: Admedus Ltd.

Medtronic expands paid family leave benefits for US employees | Personnel Moves – May 1, 2018

May 1, 2018 By Fink Densford

Medtronic (NYSE:MDT) today announced expanded paid family leave benefits which the company says will “allow for greater employee flexibility while balancing work and family priorities.” The new benefits, which went into effect today, cover full and part-time US employees and allow for a “wide range of family care leave needs,” the Fridley, Minn.-based company said. These […]

Filed Under: Business/Financial News Tagged With: Admedus Ltd., becton dickinson, C.R. Bard, Medtronic, Minnetronix Medical, Zeus Industrial Products

How to regenerate a regenerative company: Admedus CEO Paterson on the company’s turnaround efforts

June 30, 2017 By Fink Densford

For over a year, Admedus (ASX:AHZ) has been engaged in a significant restructuring effort as it looks to break trends of overspending and edge towards profitability. The company is finally seeing fruits of its labors, posting its 1st cashflow neutral quarter this year and looking to a hopeful turn to profitability in the future. To lead […]

Filed Under: Business/Financial News, Regenerative Medicine Tagged With: Admedus Ltd.

Admedus touts Phase II follow-on data for CardioCel

August 23, 2016 By Fink Densford

Admedus (ASX:AHZ) yesterday released results from the Phase II extension study of its CardioCel regenerative used to repair congenital heart defects in pediatric patients, touting no signs of calcification or need for repeat procedures. Admedus’ CardioCel bio-scaffolds are regenerative tissue patches designed for cardiac and vascular repairs and reconstructions and promote autologous growth. “This is a significant […]

Filed Under: Cardiovascular, Clinical Trials, Regenerative Medicine Tagged With: Admedus Ltd.

Admedus shares rise on hospital infusion pump supply deal with Arcomed

May 25, 2016 By Fink Densford

Admedus (ASX:AHZ) said today it won a supply contract with the new Royal Adelaide Hospital for the installation of the Arcomed chroma infusion pump systems. Swiss infusion technology company Arcomed’s Chroma infusion pumps are designed to provide a whole-of-hospital system and include LCD touch screens, drug error reduction systems and on-screen color coding of medication, Admedus said. […]

Filed Under: Business/Financial News, Drug Pumps Tagged With: Admedus Ltd., Arcomed ag

Fonar taps MR scan inventor and founder’s son as CEO | Personnel Moves

February 10, 2016 By Fink Densford

Fonar Corp (NSDQ:FONR) said yesterday it named Timothy Damadian, son of magnetic resonance scanning inventor and company founder Dr. Raymond Damadian, as its new president and CEO. The younger Damadian worked with Fonar for 16 years, eventually becoming veep of operations. He formed Fonar subsidiary Health Management Corporation of America, which manages medial and diagnostic […]

Filed Under: Business/Financial News Tagged With: Abiomed, Admedus Ltd., ALR Technologies Inc., Baxter, C.R. Bard, Cordis Corp., Dune Medical Devices Inc., Fonar Corp., Getinge, Insulet, Keystone Technologies, Maquet Cardiovascular LLC, Medtronic, Personnel Moves, Prism Medical, Turnpoint Medical, Vascular Pathways Inc., Vestagen

Admedus inks exclusive distro deal with Coroneo

January 27, 2016 By Fink Densford

Admedus (ASX:AHZ) said today it inked an exclusive distribution agreement with Coroneo to sell its Extra aortic annuloplasty ring ing and other heart valve surgery instruments in Germany and the U.K. Canada-based Coroneo’s Extra aortic ring is designed to repair aortic valves by supporting dystrophic aortic tissue and a downsized dilated valve annulus to restore proper cusp contact. “This […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Distribution Tagged With: Admedus Ltd., Coroneo

Down-under medtech firm Admedus looks to future in bio-scaffolds

September 11, 2015 By Fink Densford

Australian med-tech company Admedus (ASX:AHZ) is looking to become the “gold standard” in cardiac bio-scaffolds and expand their product into other realms to promote rebuilding of tissue over artificial replacements. Admedus COO Julian Chick spoke to MassDevice.com yesterday about the company’s flagship product CardioCel, how its using bio-scaffolds to grow in the cardiac repair market and […]

Filed Under: Cardiovascular, Implants, Regenerative Medicine, Vascular Tagged With: Admedus Ltd.

Admedus releases new CardioCel scaffold in U.S.

May 18, 2015 By Fink Densford Leave a Comment

Admedus releases new CardioCel scaffold in U.S.

Admedus (ASX:AHZ) announced the U.S. launch of a new CardioCel bioscaffold designed for vascular repairs.

Filed Under: News Well, Regenerative Medicine, Vascular Tagged With: Admedus Ltd.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy